NASDAQ •
Healthcare •
Biotechnology •
Quote as of 08/04/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization6.41 mln
Float0.81 mln
Earnings Date10/01/2026
Piotroski F-Score
1
/ 9
Very weak
Beneish M-Score
-0.35
Highly suspicious
Relative Strength
34
/ 100
Underperforming
Debt / Equity
0.03
Debt-free
ROE
-122
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Founded in 2002 and headquartered in Geneva, Switzerland, Addex Therapeutics is a pharmaceutical company focused on developing oral drug treatments for neurological conditions. Its most advanced program, Dipraglurant, is being studied in clinical trials for recovery after stroke or brain injury and for managing movement problems caused by Parkinson's disease medication. The company is also advancing additional drug candidates targeting pain, anxiety, addiction, cough, and bladder conditions. Addex works alongside partners Janssen Pharmaceuticals and Indivior PLC to develop and bring these treatments to patients.
